Yıl: 2019 Cilt: 26 Sayı: 3 Sayfa Aralığı: 320 - 327 Metin Dili: Türkçe DOI: 10.17343/sdutfd.535002 İndeks Tarihi: 24-06-2020

KRONİK MİYELOİD LÖSEMİDE TANI ANINDA İLAVE KROMOZOMAL ABNORMALİTELER VE VARYANT PHİLADEPHİA TRANSLOKASYONLARI; TEK MERKEZ DENEYİMİ

Öz:
AmaçKronik miyeloid lösemi (KML) hastalarında Philadelphia (Ph) kromozomunun yanında, ilave kromozom anomalilerin varlığı hastalık progresyonu ile ilişkiliklonal evrimi göstermektedir. Bu nedenle, geniş hasta serilerinde sitogenetik analiz sonuçlarının değerlendirilmesi, KML hastalarında tanı kadar, hastalığın prognozu açısından da büyük öneme sahiptir.Gereç ve YöntemBu çalışmada, KML tanılı 225 hastanın kemik iliği örneklerinden elde edilmiş sitogenetik ve FISH analiz sonuçları retrospektif olarak incelenmiştir.Bulgular225 hastanın 15’inde (%6,7) klasik Ph kromozomuna ilave kromozomal abnormalite belirlenmiştir. Bu hastalardan 2’sinde minör rota (%0,9), 10’unda majör rota(%4,4) kromozom anomalileri, ayrıca 3 hastada sırasıyla ilave kromozom anomalisi olarak t(8;19), t(5;7) ve 16.kromozomun kaybı gözlenmiştir. İlave kromozomal abnormaliteler içerisinde en yaygın olarak ikinci bir Ph kromozomunun varlığı ve bunu takiben 8 ve 19 numaralı kromozomların trizomisi belirlenmiştir. 225 hastanın 7’sinde (%3,1) ise varyant philadelphia kromozom translokasyonu gösterilmiştir ve bu varyant translokasyonlardan t(X;9;22)( p11.4;q34;q11) ve t(20;9;22)(p13;q34;q11) ise bizim çalışmamızda ilk kez rapor edilmiştir.SonuçÇalışmamızda sonuç olarak, t(9;22) translokasyonuna ilave kromozom abnormalitelerinin ve varyant Ph translokasyonlarının KML kliniği ile ilişkisi ve literatüre göre değerlendirilmesi yapılmıştır.
Anahtar Kelime:

ADDITIONAL CHROMOSOMAL ABNORMALITIES AND VARIANT PHILADEPHIA TRANSLOCATIONS IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA; A SINGLE CENTER EXPERIENCE

Öz:
Objective In addition to the Philadelphia (Ph) chromosome in patients with chronic myeloid leukemia (CML), the presence of additional chromosomal abnormalities indicates clonal evolution associated with disease progression. Therefore, the evaluation of cytogenetic analysis results in large patient series is of great importance in terms of prognosis of the disease as well as diagnosis in CML patients. Material and Method In this study, cytogenetic and FISH analysis results of bone marrow samples of 225 CML patients were analyzed retrospectively.Results In 15 of 225 patients (6.7%), additional chromosomal abnormalities to classical Ph chromosome were detected. Of these patients, 2 had minor rota (0.9%), 10 had major rota (4.4%) chromosomal anomalies, and 3 had additional chromosomal anomaly t(8;9), t(5; 7) and loss of chromosome 16 were observed. Most commonly, the presence of a second Ph chromosome, followed by the trisomy of chromosomes 8 and 19 was determined among additional chromosomal abnormalities. In 7 of 225 patients (3.1%), variant Philadelphia chromosome translocation was shown and from these variant translocations t(X;9;22)(p11.4;q34;q11) and t(20;9;22)(p13;q34;q11) has been reported for the first time in our study.Conclusion As a result, in our study, the association of additional chromosomal abnormalities and variant Ph translocations with CML clinic and evaluation according to the literature were made.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
0
0
0
  • 1. Hehlmann R, Hochhaus A, Baccarani M; European LeukemiaNet. Chronic myeloid leukaemia. Lancet 2007;370:342-50.
  • 2. Crisan AM, Coriu D, Arion C, Colita A, Jardan C. The impact of additional cytogenetic abnormalities at diagnosis and during therapy with tyrosine kinase inhibitors in Chronic Myeloid Leukaemia. J Med Life. 2015 Oct-Dec;8(4):502-8.
  • 3. Cortes JE, Talpaz M, Giles F, O’Brien S, Rios MB, Shan J et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood. 2003;101(10): 3794-3800.
  • 4. O’Dwyer ME, Mauro MJ, Blasdel C, Farnsworth M, Kurilik G, Hsieh YC et al. Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. Blood. 2004;103(2):451-455.
  • 5. Skorski T. BCR/ABL, DNA damage and DNA repair: Implications for new treatment concepts. Leuk Lymphoma. 2008;49(4):610- 614.
  • 6. Safaei A, Monabati A, Safavi M, Atashabparvar A, Hosseini M. Additional cytogenetic aberrations in chronic myeloid leukemia: a single-center experience in the Middle East. Blood Res. 2018 Mar;53(1):49-52. doi: 10.5045/br.2018.53.1.49.
  • 7. Syed NN, Usman M, Adil S, Khurshid M. Additional chromosomal abnormalities in Philadelphia-positive chronic myeloid leukemia. Hematol Oncol Stem Cell Ther. 2008 JulSep;1(3):166-70.
  • 8. Mitelman F, Levan G, Nilsson PG, Brandt L. Nonrandom karyotypic evolution in chronic myeloid leukemia. Int J Cancer. 1976;18(1):24-30.
  • 9. Mitelman F. The Cytogenetic Scenario of Chronic Myeloid Leukemia. Leuk Lymphoma. 1993; 11(s1):11-15.
  • 10. Millot F, Dupraz C, Guilhot J, Suttorp M, Brizard F, Leblanc T et al. Additional cytogenetic abnormalities and variant t(9;22) at the diagnosis of childhood chronic myeloid leukemia: The experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents. Cancer. 2017 Sep 15;123(18):3609-3616. doi: 10.1002/cncr.30767.
  • 11. Bacher U, Haferlach T, Hiddemann W, Schnittger S, Kern W,Schoch C. Additional clonal abnormalities in Philadelphia-positive ALL and CML demonstrate a different cytogenetic pattern at diagnosis and follow different pathways at progression. Cancer Genet Cytogenet. 2005 Feb;157(1):53-61.
  • 12. McGowan-Jordan J,‎ Simons A,‎ Schmid M. ISCN 2016: An International System for Human Cytogenomic Nomenclature (2016) Cytogenetic and Genome Research 2016, Vol. 149, No. 1-2 1st Edition
  • 13. Fabarius A, Leitner A, Hochhaus A, Müller MC, Hanfstein B, Haferlach C et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood. 2011 Dec 22;118(26):6760-8. doi: 10.1182/blood-2011-08-373902
  • 14. Luatti S, Castagnetti F, Marzocchi G, Baldazzi C, Gugliotta G, Iacobucci I et al; Gruppo Italiano Malat-tie Ematologiche dell’Adulto (GIMEMA) Working Party on CML. Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. Blood. 2012;120: 761-767.
  • 15. O’Dwyer ME, Gatter KM, Loriaux M, Druker BJ, Olson SB, Magenis RE et al. Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. Leukemia 2003;17: 481-7.
  • 16. Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat. Rev. Cancer. 2007 Jun;7(6):441–453. doi: 10.1038/nrc2147.
  • 17. Anastasi J, Feng J, Le Beau MM, Larson RA, Rowley JD, Vardiman JW. The relationship between secondary chromosomal abnormalities and blast transformation in chronic myelogenous leukemia. Leukemia. 1995 Apr;9(4):628–633.
  • 18. Kantarjian HM, Keating MJ, Smith TL, Talpaz M, McCredie KB. Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia. Am J Med. 1990 Jan;88(1):1-8.
  • 19. Cortes JE, Talpaz M, O’Brien S, Faderl S, Garcia-Manero G, Ferrajoli A et al. Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal. Cancer. 2006;106:1306-1315.
  • 20. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al. European Leukemia-Net recommendations for the management of chronic myeloid leu-kemia:2013. Blood. 2013;122:872-884.
  • 21. Albano F, Specchia G, Anelli L, Zagaria A, Storlazzi CT, Buquicchio C et al. Genomic deletions on other chromosomes involved in variant t(9;22) chronic myeloid leukemia cases. Genes Chromosomes Cancer 2003;36:353-60. 12.
  • 22. El-Zimaity MM, Kantarjian H, Talpaz M, O’Brien S, Giles F, Garcia-Manero G et al. Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. Br J Haematol 2004;125:187-95.
  • 23. Marzocchi G, Castagnetti F, Luatti S, Baldazzi C, Stacchini M, Gugliotta G et al. Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. Blood. 2011;117:6793-6800.
  • 24. Gorusu M, Benn P, Li Z, Fang M. On the genesis and prognosis of variant translocations in chronic myeloid leukemia. Cancer Genet Cytogenet. 2007;173:97-106.
  • 25. Eyüpoğlu D, Bozkurt S, Haznedaroğlu İ, Büyükaşık Y, Güven D. The impact of variant Philadelphia chromosome translocations on the clinical course of chronic myeloid leukemia. Turk J Haematol 2016;33:60-5.
  • 26. Legues ME, Encina A, Valenzuela M, Palma T, Undurraga MS. Cytogenetic and molecular characteristics of 25 Chilean patients with a variant Ph translocation. Cancer Genet. 2011 Jul;204(7):410-2. doi: 10.1016/j.cancergen.2011.06.004.
  • 27. Turchini MF, Geneix A, Delarocque A, Mathe O, Carsuza D, Malet P. Translocation (2;9;22) in chronic myelogenous leukemia (CML). Cancer Genet Cytogenet. 1984 Feb;11(2):221-2.
  • 28. Guillaume B, Ameye G, Libouton JM, Dierlamm J, Vaerman JL, Straetmans N et al. Chronic myeloid leukemia with a rare variant Philadelphia translocation; t(9;22;21)(q34;q11;q22). Cancer Genet Cytogenet. 2000 Jan 15;116(2):166-9.
  • 29. Jeandidier E, Dastugue N, Mugneret F, Lafage-Pochitaloff M, Mozziconacci MJ, Herens C et al.; Groupe Français de Cytogénétique Hématologique (GFCH). Abnormalities ofthe long arm of chromosome 21 in 107 patients with hematopoieticdisorders:a collaborative retrospective study of the Groupe Français de Cytogénétique Hématologique. Cancer Genet Cytogenet. 2006 Apr 1;166(1):1-11.
  • 30. Dube I, Dixon J, Beckett T, Grossman A, Weinstein M, Benn P et al. Location of breakpoints within the major breakpoint cluster region (bcr) in 33 patients with bcr rearrangement-positive chronic myeloid leukemia (CML) with complex or absent Philadelphia chromosomes. Genes Chromosomes Cancer. 1989 Vol 1:106-111
  • 31. Naumann S, Decker HJ. Genesis of variant Philadelphia chromosome translocations in chronic myelocytic leukemia. Cancer Genet Cytogenet. 2003 Nov;147(1):18-22.
  • 32. Richebourg S, Eclache V, Perot C, Portnoi MF, Van den Akker J, Terré C et al.; Fi-LMC Group. Mechanisms of genesis of variant translocation in chronic myeloid leukemia are not correlated with ABL1 or BCR deletion status or response to imatinib therapy. Cancer Genet Cytogenet. 2008 Apr 15;182(2):95-102. doi: 10.1016/j.cancergencyto.2008.01.005.
  • 33. Costa D, Carrió A, Madrigal I, Arias A, Valera A, Colomer D et al. Studies of complex Ph translocations in cases with chronic myelogenous leukemia and one with acute lymphoblastic leukemia. Cancer Genet Cytogenet. 2006 Apr 1;166(1):89-93.
  • 34. Hsiao HH, Liu YC, Tsai HJ, Hsu JF, Yang WC, Chang CS, Lin SF. Additional chromosome abnormalities in chronic myeloid leukemia. Kaohsiung J Med Sci. 2011 Feb;27(2):49-54. doi: 10.1016/j.kjms.2010.09.001.
  • 35. Reid AG, Huntly BJ, Grace C, Green AR, Nacheva EP. Survival implications of molecular heterogeneity in variant Philadelphia-positive chronic myeloid leukaemia. Br J Haematol. 2003 May;121(3):419-27.
  • 36. Bennour A, Sennana H, Laatiri MA, Elloumi M, Khelif A, Saad A. Molecular cytogenetic characterization of variant Philadelphia translocations in chronic myeloid leukemia: genesis and deletion of derivative chromosome 9.Cancer Genet Cytogenet. 2009 Oct;194(1):30-7. doi: 10.1016/j.cancergencyto.2009.05.010.
  • 37. Costa D, Carrió A, Madrigal I, Arias A, Valera A, Colomer D et al. Studies of complex Ph translocations in cases with chronic myelogenous leukemia and one with acute lymphoblastic leukemia. Cancer Genet Cytogenet. 2006 Apr 1;166(1):89-93.
  • 38. Dubé I, Dixon J, Beckett T, Grossman A, Weinstein M, Benn P et al. Location of breakpoints within the major breakpoint cluster region (bcr) in 33 patients with bcr rearrangement-positive chronic myeloid leukemia (CML) with complex or absent Philadelphia chromosomes. Genes Chromosomes Cancer. 1989 Sep;1(1):106-11.
  • 39. Duhoux FP, Ameye G, Lambot V, Herens C, Lambert F, Raynaud S et al. Refinement of 1p36 alterations not involving PRDM16 in myeloid and lymphoid malignancies. PLoS One. 2011;6(10):e26311. doi: 10.1371/journal.pone.0026311.
  • 40. Fabarius A, Kalmanti L, Dietz CT, Lauseker M, Rinaldetti S, Haferlach C et al. Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML. Ann Hematol. 2015 Dec;94(12):2015-24. doi: 10.1007/s00277-015- 2494-9.
  • 41. Lee SE, Choi SY, Bang JH, Kim SH, Jang EJ, Byeun JY et al. The long-term clinical implications of clonal chromosomal abnormalities in newly diagnosed chronic phase chronic myeloid leukemia patients treated with imatinib mesylate. Cancer Genet. 2012 Nov;205(11):563-71. doi: 10.1016/j.cancergen.2012.09.003.
  • 42. Markovic VD, Bouman D, Bayani J, Al-Maghrabi J, Kamel-Reid S, Squire JA. Lack of BCR/ABL reciprocal fusion in variant Philadelphia chromosome translocations: a use of double fusion signal FISH and spectral karyotyping. Leukemia. 2000 Jun;14(6):1157-60.
  • 43. Meza Espinoza JP, Judith Picos Cárdenas V, Gutiérrez-Angulo M, González García JR. Secondary chromosomal changes in 34 Philadelphia-chromosome-positive chronic myelocytic leukemia patients from the Mexican West. Cancer Genet Cytogenet. 2004 Jan 15;148(2):166-9.
  • 44. Yehuda O, Abeliovich D, Ben-Neriah S, Sverdlin I, Cohen R, Varadi G et al. Clinical implications of fluorescence in situ hybridization analysis in 13 chronic myeloid leukemia cases: Ph-negative and variant Ph-positive. Cancer Genet Cytogenet. 1999 Oct 15;114(2):100-7.
  • 45. Van der Plas DC, Hermans AB, Soekarman D, Smit EM, de Klein A, Smadja N et al. Cytogenetic and molecular analysis in Philadelphia negative CML. Blood. 1989 Mar;73(4):1038-44.
APA Aydin C, ÇETIN Z, YÜCEL O, Iltar U, SALİM O, BERKER KARAÜZÜM S (2019). KRONİK MİYELOİD LÖSEMİDE TANI ANINDA İLAVE KROMOZOMAL ABNORMALİTELER VE VARYANT PHİLADEPHİA TRANSLOKASYONLARI; TEK MERKEZ DENEYİMİ. , 320 - 327. 10.17343/sdutfd.535002
Chicago Aydin Cigdem,ÇETIN ZAFER,YÜCEL Orhan Kemal,Iltar Utku,SALİM Ozan,BERKER KARAÜZÜM Sibel KRONİK MİYELOİD LÖSEMİDE TANI ANINDA İLAVE KROMOZOMAL ABNORMALİTELER VE VARYANT PHİLADEPHİA TRANSLOKASYONLARI; TEK MERKEZ DENEYİMİ. (2019): 320 - 327. 10.17343/sdutfd.535002
MLA Aydin Cigdem,ÇETIN ZAFER,YÜCEL Orhan Kemal,Iltar Utku,SALİM Ozan,BERKER KARAÜZÜM Sibel KRONİK MİYELOİD LÖSEMİDE TANI ANINDA İLAVE KROMOZOMAL ABNORMALİTELER VE VARYANT PHİLADEPHİA TRANSLOKASYONLARI; TEK MERKEZ DENEYİMİ. , 2019, ss.320 - 327. 10.17343/sdutfd.535002
AMA Aydin C,ÇETIN Z,YÜCEL O,Iltar U,SALİM O,BERKER KARAÜZÜM S KRONİK MİYELOİD LÖSEMİDE TANI ANINDA İLAVE KROMOZOMAL ABNORMALİTELER VE VARYANT PHİLADEPHİA TRANSLOKASYONLARI; TEK MERKEZ DENEYİMİ. . 2019; 320 - 327. 10.17343/sdutfd.535002
Vancouver Aydin C,ÇETIN Z,YÜCEL O,Iltar U,SALİM O,BERKER KARAÜZÜM S KRONİK MİYELOİD LÖSEMİDE TANI ANINDA İLAVE KROMOZOMAL ABNORMALİTELER VE VARYANT PHİLADEPHİA TRANSLOKASYONLARI; TEK MERKEZ DENEYİMİ. . 2019; 320 - 327. 10.17343/sdutfd.535002
IEEE Aydin C,ÇETIN Z,YÜCEL O,Iltar U,SALİM O,BERKER KARAÜZÜM S "KRONİK MİYELOİD LÖSEMİDE TANI ANINDA İLAVE KROMOZOMAL ABNORMALİTELER VE VARYANT PHİLADEPHİA TRANSLOKASYONLARI; TEK MERKEZ DENEYİMİ." , ss.320 - 327, 2019. 10.17343/sdutfd.535002
ISNAD Aydin, Cigdem vd. "KRONİK MİYELOİD LÖSEMİDE TANI ANINDA İLAVE KROMOZOMAL ABNORMALİTELER VE VARYANT PHİLADEPHİA TRANSLOKASYONLARI; TEK MERKEZ DENEYİMİ". (2019), 320-327. https://doi.org/10.17343/sdutfd.535002
APA Aydin C, ÇETIN Z, YÜCEL O, Iltar U, SALİM O, BERKER KARAÜZÜM S (2019). KRONİK MİYELOİD LÖSEMİDE TANI ANINDA İLAVE KROMOZOMAL ABNORMALİTELER VE VARYANT PHİLADEPHİA TRANSLOKASYONLARI; TEK MERKEZ DENEYİMİ. Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi, 26(3), 320 - 327. 10.17343/sdutfd.535002
Chicago Aydin Cigdem,ÇETIN ZAFER,YÜCEL Orhan Kemal,Iltar Utku,SALİM Ozan,BERKER KARAÜZÜM Sibel KRONİK MİYELOİD LÖSEMİDE TANI ANINDA İLAVE KROMOZOMAL ABNORMALİTELER VE VARYANT PHİLADEPHİA TRANSLOKASYONLARI; TEK MERKEZ DENEYİMİ. Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi 26, no.3 (2019): 320 - 327. 10.17343/sdutfd.535002
MLA Aydin Cigdem,ÇETIN ZAFER,YÜCEL Orhan Kemal,Iltar Utku,SALİM Ozan,BERKER KARAÜZÜM Sibel KRONİK MİYELOİD LÖSEMİDE TANI ANINDA İLAVE KROMOZOMAL ABNORMALİTELER VE VARYANT PHİLADEPHİA TRANSLOKASYONLARI; TEK MERKEZ DENEYİMİ. Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi, vol.26, no.3, 2019, ss.320 - 327. 10.17343/sdutfd.535002
AMA Aydin C,ÇETIN Z,YÜCEL O,Iltar U,SALİM O,BERKER KARAÜZÜM S KRONİK MİYELOİD LÖSEMİDE TANI ANINDA İLAVE KROMOZOMAL ABNORMALİTELER VE VARYANT PHİLADEPHİA TRANSLOKASYONLARI; TEK MERKEZ DENEYİMİ. Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi. 2019; 26(3): 320 - 327. 10.17343/sdutfd.535002
Vancouver Aydin C,ÇETIN Z,YÜCEL O,Iltar U,SALİM O,BERKER KARAÜZÜM S KRONİK MİYELOİD LÖSEMİDE TANI ANINDA İLAVE KROMOZOMAL ABNORMALİTELER VE VARYANT PHİLADEPHİA TRANSLOKASYONLARI; TEK MERKEZ DENEYİMİ. Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi. 2019; 26(3): 320 - 327. 10.17343/sdutfd.535002
IEEE Aydin C,ÇETIN Z,YÜCEL O,Iltar U,SALİM O,BERKER KARAÜZÜM S "KRONİK MİYELOİD LÖSEMİDE TANI ANINDA İLAVE KROMOZOMAL ABNORMALİTELER VE VARYANT PHİLADEPHİA TRANSLOKASYONLARI; TEK MERKEZ DENEYİMİ." Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi, 26, ss.320 - 327, 2019. 10.17343/sdutfd.535002
ISNAD Aydin, Cigdem vd. "KRONİK MİYELOİD LÖSEMİDE TANI ANINDA İLAVE KROMOZOMAL ABNORMALİTELER VE VARYANT PHİLADEPHİA TRANSLOKASYONLARI; TEK MERKEZ DENEYİMİ". Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi 26/3 (2019), 320-327. https://doi.org/10.17343/sdutfd.535002